Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death

Cancer

Volumn 116, Issue 8, 2010, Pages 1887-1892

  Choueiri, Toni K ^a   Chen, Ming Hui ^b   D'Amico, Anthony V ^a   Sun, Leon ^c   Nguyen, Paul L ^a   Hayes, Julia H ^a   Robertson, Cary N ^c   Walther, Philip J ^c   Polascik, Thomas J ^c   Albala, David M ^c   Moul, Judd W ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hormonal therapy; Prostate specific antigen; Prostatectomy; Radiotherapy; Time dependent covariate

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SALVAGE THERAPY;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RECURRENCE; RISK; SALVAGE THERAPY; TIME FACTORS; TREATMENT FAILURE;

EID: 77950968988     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25013     Document Type: Article

References (18)

1. Moul JW, Bañez LL, Freedland SJ. Rising PSA in nonmetastatic prostate cancer. Oncology (Williston Park). 2007;21:1436-1445; discussion 1449, 1452, 1454.
2. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006;24:3973-3978.
3. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
4. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439. (Pubitemid 41124175)
5. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
6. Jhaveri FM, Zippe CD, Klein EA, et al. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999;54:884-890.
7. Trapasso JG, deKernion JB, Smith RB, et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994;152:1821-1825. (Pubitemid 24322638)
8. Trock BJ, Han M, Freedland SJ, et al. Impact of salvage androgen deprivation therapy on overall survival in men with biochemical recurrence after radical prostatectomy. J Urol.2009;181:458.
9. Greene FL, Balch CM, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
10. Agresti A, ed. An Introduction to Categorical Data Analysis. 2nd ed. New York: John Wiley & Sons; 2002: 16-52.
11. Hollander M, Wolfe DA. Nonparametric Statistical Methods. 2nd ed. New York: John Wiley & Sons; 1999:106-140.
12. Klein JP, Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In: Klein JP, Moeschberger ML, eds. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York: Springer; 2003:243-293.
13. Klein JP, Moeschberger ML. Refinements of the semiparametric proportional hazards model. In: Klein JP, Moeschberger ML, eds. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York: Springer; 2003:295-328.
14. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-545. (Pubitemid 46054056)
15. Neter J, Wasserman W, Kutner M, et al. Simultaneous inferences and other topics in regression analyses-1. In: Applied Linear Regression Models. Homewood, Ill: Irwin Professional Publishing; 1983:150-153.
16. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597. (Pubitemid 29211767)
17. Nakamura M, Hasumi H, Miyoshi Y, et al. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Int J Urol. 2005;12:1050-1054. (Pubitemid 43110217)
18. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299:2760-2769. (Pubitemid 351846851)